Transcript Document

Acceleration Mass Spectrometer
for biomedicine using
Vasily, Parkhomchuk, Budker Institute of Nuclear Physics Siberian
Division Russian Academy of Science, Novosibirsk
[email protected]
Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia”
28-29 September 2012, Saint-Petersburg
Description of the solution and technology
Description of technology: Isotopic marks at drug or food for investigation of dynamic
distribution and decay inside body. The radioactive isotopes were first used in medicine
for diagnostic procedures during the early 1930s. This eventually laid the foundation for
nuclear medicine. AMS is a highly sensitive method of counting atoms. It is used to detect
very low concentrations of natural isotopic abundances (typically in the range between
10-12 and 10-16of both radionuclides and stable nuclides. The main advantages of AMS
compared to conventional radiometric methods are the use of smaller samples (mg and
even sub-mg size) and shorter measuring times (less than 1 hr).
The remarkable sensitivity of AMS opens the way to a host of other new diagnostic tests
as well: assays for early detection of various disorders, tests that determine the efficacy
of therapeutic regimens, studies of how the body handles various nutrients and vitamins,
and assessment of the effects of environmental substances and toxins. When combined
with such imaging technologies as magnetic resonance imaging, accelerator mass
spectrometry will be able to assess changes in tissues, hormone levels, and metabolites in
real time.
In the biochemical field, synthesized 14C labeled compounds can be administered as a
tracer dose for in-vivo human metabolic and drug studies which require AMS analysis of
graphitized biological samples
Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia”
28-29 September 2012, Saint-Petersburg
Current condition and prospects of development:
ref. units
10
0
10
-1
10
-2
10
-3
10
-4
10
-5
10
-6
10
-7
10
-8
10
-9
10
-10
10
-11
10
-12
10
-13
10
-14
10
-15
10
-16
11
First AMS prototype was made
14
M
at BINP 2009
Fig show low energy spectra
M12 =1, M 14 =10-14 molecular ions
14
C
modern
sample
But after pass AMS and clearing
"dead"
sample
12
13
14
mass
15
16
molecular ion,
17
Sample from modern tree
M 14 =10-12 clear viseable
Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia”
28-29 September 2012, Saint-Petersburg
Description of the solution
 Description of novelty: in brief (short) arguments of novelty
 Current condition and prospects of development: current status and planned steps that will be
created as a result of R & D
 The potential for building a relationship with one of the world leaders company in the project
implementation on the world market: it depend from development our equipments. Good
design and high level reliability can open windows for collaborations
Compact AMS for 6*9 m*m room
Sample measuring rate about
200/day
Preliminary prise 3M$
Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia”
28-29 September 2012, Saint-Petersburg
Market
On what market segment is focused your product- biology, pharmaceutical industry, ecology,
safety systems- food, water, industry isotopic marking
Current solutions in the market and the key advances or uniqueness of your product
Potential consumers of the product (target). List of your product users, consumers (5-10
companies)-
Demand on your product on market segment
(pcs, unit)
2014 – 2025
10 units/year
Assessment of the global market,
All market now about 10-30/year
Price about 3 M$/unit 30-90 M$/year
Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia”
28-29 September 2012, Saint-Petersburg
Investor of the project realization (implementation)
 Привлеченные инвесторы или, если инвестор не привлечен, то для каких
компаний, фондов, частных лиц и др. по мнению Разработчика проект может п
 Existing investors. In case if there is not investor, for which companies,
foundations, individuals, and others according to the project developer opinion
could be promoted as commercial interest
Can order about 10 units for biomedicine using inside
former USSR counties
Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia”
28-29 September 2012, Saint-Petersburg
Cooperation for the project
Is not clear now. Inside Russia exist few institutes that interested collaboration of
this technology. From other countries it was few discussions on conferences
Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia”
28-29 September 2012, Saint-Petersburg
Project team
Budker Institute of Nuclear Physics
Parkhomchuk V.V., RastegeevS.A.
R&D, production of prototype
First experiments with samples
Institute of Catalyze
Okunev A.G.
Sample productions
Novosibirsk State University
Bondar A.E.
Guliaeva L.F.
Biomedicine experiment on existing
Education specialists at NGU
Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia”
28-29 September 2012, Saint-Petersburg